New Jersey 2022-2023 Regular Session

New Jersey Senate Bill S952

Introduced
1/31/22  

Caption

Requires persons picking up prescriptions for Schedule II controlled dangerous substances to present identification.

Impact

If enacted, S952 will amend existing laws by embedding stricter controls on the dispensation of Schedule II CDS. It seeks to provide law enforcement and health officials with improved means to track prescription patterns and identify misuse or illegal distribution of these substances. The bill's requirement for logbooks will ensure that pharmacists maintain accurate records and can aid in investigations related to drug recalls or law enforcement inquiries.

Summary

Senate Bill S952 aims to control the dispensing of Schedule II controlled dangerous substances (CDS) by mandating that individuals authorized to possess such substances present valid photographic identification before their prescriptions are filled. The bill also requires the pharmacist to maintain a logbook where the individual's name, address, and the date and time of dispensation are recorded. This action aims to enhance safety and accountability in the handling of potentially dangerous medications, as these substances have a high potential for abuse and dependence.

Contention

Notable points of contention include the implications of such strict identification requirements on patients, particularly those who may lack proper documentation or are vulnerable populations. Critics argue that while the intention is to curtail abuse, it may inadvertently restrict access to necessary medications for legitimate patients. Supporters assert that the bill is a necessary step towards monitoring and mitigating the opioid crisis, while opponents caution against potential barriers to patients in need of pain management.

Additional_info

The bill also includes a provision that ensures logbook information is protected from public disclosure except in cases necessary for public health safety or law enforcement. This aims to balance the need for tracking prescription drugs against individual privacy rights.

Companion Bills

No companion bills found.

Previously Filed As

NJ S2517

Requires person picking up prescriptions for Schedule II controlled dangerous substances to present identification.

NJ A5488

Classifies xylazine as Schedule III controlled dangerous substance under certain circumstances; requires reporting of xylazine prescriptions.

NJ SB594

Relating to the regulation of prescriptions for controlled substances, including certain procedures applicable to electronic prescriptions for Schedule II controlled substances.

NJ HB2246

Relating to certain procedures applicable to electronic prescriptions for Schedule II controlled substances.

NJ SB1338

Controlled dangerous substances; modifying certain definitions; modifying Schedule I and Schedule III. Effective date.

NJ SB134

Provides relative to prescriptions for controlled dangerous substances. (8/1/18)

NJ SB1109

Controlled substances: Schedule II drugs: opioids.

NJ HB174

Provides with respect to the scheduling of controlled dangerous substances

NJ HB3073

Controlled dangerous substances; adding exception to opioid prescription requirements.

NJ HB3567

Controlled dangerous substances; adding to list of Schedule I controlled substances; revocation or suspension of registrations; written orders; repealers; emergency.

Similar Bills

CA AB40

CURES database: health information technology system.

NJ S2517

Requires person picking up prescriptions for Schedule II controlled dangerous substances to present identification.

CA AB1341

Public health: oral therapeutics.

CA AB1752

Controlled substances: CURES database.

CA AB401

Pharmacy: remote dispensing site pharmacy: telepharmacy: shared clinic office space.

CA SB641

Mexican prepaid health plans.

AZ SB1569

Pharmacy technician trainees; pharmacists; compounding